In fact, targeting eIF4E, a key translational initiation complex (TIC) protein, using chemical inhibitors like Ribavarin has shown potential to reduced tumorigenic growth in xenograft mouse models as well as early clinical trials in AML (acute myeloid leukemia)10,11. Here, EIF4E is linked to acute myeloid leukemia.